Zobrazeno 1 - 10
of 124
pro vyhledávání: '"J. Vinholes"'
Autor:
Jens Huober, Hatem A. Azim, Debora Fumagalli, Martine Piccart-Gebhart, L de la Pena, Giacomo Bregni, S. Di Cosimo, Giulia Galli, Christine Campbell, Carmen Criscitiello, W. M.J. Ng, Marco Colleoni, J. Vinholes, A. Patel, A. Ferro, Giuseppe Curigliano, E. de Azambuja, Miguel Izquierdo, L. Fein, Bjørn Naume, José Baselga
Publikováno v:
European Journal of Cancer. 89:42-48
To determine the value of mammography and breast ultrasound (US) in predicting outcomes in HER2 positive breast cancer patients (pts) within Neo-ALTTO trial.Mammography and US were required at baseline, week 6 and surgery. Two independent blinded inv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::791b052eaefad926f5934c330b159f4c
https://doi.org/10.1016/j.ejca.2017.10.036
https://doi.org/10.1016/j.ejca.2017.10.036
Autor:
Roberto Torres, P López-Álvarez, Carlos Sampaio, Carlos Barrios, E Villar, Eva Carrasco, A. Lluch, L Pérez-Michel, J.G.M. Segalla, S. Reyes, JA Garcia-Saenz, J. Cárdenas, Maria Jose Godes, M. Ramos, J Castellanos, A. Ruiz, M. J. Escudero, E Martínez de Dueñas, Lourdes Calvo, J Moncayo, J. M. Baena, Manuel Ruiz-Borrego, J. Vinholes, L Torrecillas, Susana Bezares, M. Martin, Henry L. Gomez, Agust Barnadas, M. A. Seguí, Antonio Llombart, Gilberto Luiz da Silva Amorim, J. Bines, Álvaro Rodríguez-Lescure, M Rodríguez de la Borbolla, Antonio Antón, J de la Haba, B Cardemil, E Garcia
Publikováno v:
Cancer Research. 79:GS2-04
Background: Triple negative breast cancers (TNBC) have a greater risk of relapse than non-TNBC. New therapeutic approaches are needed for these patients (pts). CIBOMA/2004-01_GEICAM/2003-11 is a multinational, randomized phase III trial exploring adj
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0aebf64b3256301578ee24865dcc030
https://doi.org/10.1158/1538-7445.sabcs18-gs2-04
https://doi.org/10.1158/1538-7445.sabcs18-gs2-04
Publikováno v:
Annals of Oncology. 20:1157-1162
Most breast tumors depend on female sex hormones for development and growth, thus being amenable to endocrine therapies. In the management of estrogen receptor (ER)-positive, advanced breast cancer, conventional wisdom dictates the use of endocrine t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7d7cd322c705befd238c9e500f1b091
https://doi.org/10.1093/annonc/mdn756
https://doi.org/10.1093/annonc/mdn756
Autor:
Louis Lacombe, Ming Zheng, Donald M. Gleason, Simon Tchekmedyian, J. Allen Goas, Joseph L. Chin, Peter Venner, Fred Saad, Robin Murray, Jeferson J. Vinholes
Publikováno v:
JNCI Journal of the National Cancer Institute. 96:879-882
In a placebo-controlled randomized clinical trial, zoledronic acid (4 mg via a 15-minute infusion every 3 weeks for 15 months) reduced the incidence of skeletal-related events (SREs) in men with hormone-refractory metastatic prostate cancer. Among 12
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5ef082b6a92d69f84e563247305db72
https://doi.org/10.1093/jnci/djh141
https://doi.org/10.1093/jnci/djh141
Autor:
Joseph L. Chin, Louis Lacombe, Robin Murray, Fred Saad, Simon Tchekmedyian, J. Allen Goas, Bee Chen, Peter Venner, Jeferson J. Vinholes, Donald M. Gleason
Publikováno v:
JNCI Journal of the National Cancer Institute. 94:1458-1468
Background: Bone metastases are a common cause of morbidity in patients with prostate carcinoma. We studied the effect of a new bisphosphonate, zoledronic acid, which blocks bone destruction, on skeletal complications in prostate cancer patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::49918e251f2dd3f4044f6c99bd3c435f
https://doi.org/10.1093/jnci/94.19.1458
https://doi.org/10.1093/jnci/94.19.1458
Autor:
J. Eremin, Wolfgang Eiermann, J. Appfelstaedt, Louis Mauriac, M. Dugan, J. Vinholes, Vladimir Semiglazov, Antonio Llombart-Cussac, S. Paepke, H. A. Chaudri-Ross, M. Lassus, Mieke Borgs, Matthew J. Ellis
Publikováno v:
Annals of Oncology. 12:1527-1532
Background: A randomized, double-blind, multicenter study was conducted to compare the anti-tumor activity of letrozole vs. tamoxifen in postmenopausal women with ER and/or PgR positive primary untreated breast cancer. Patients and methods: Three hun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e3decaa6ab182dca32daf7d9d4753b7
https://doi.org/10.1023/a:1013128213451
https://doi.org/10.1023/a:1013128213451
Publikováno v:
Progress in Palliative Care. 4:39-43
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93f87af82d51819490765043969cbb9a
https://doi.org/10.1080/09699260.1996.11746735
https://doi.org/10.1080/09699260.1996.11746735
Publikováno v:
Acta Oncologica. 35:23-29
Bisphosphonates, in conjunction with rehydration, are now the treatment of choice for hypercalcaemia of malignancy. They can also relieve bone pain and improve quality of life as single agent therapy and, in conjunction with systemic anticancer treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aad330d66f567d4edb0325cc761c1d3b
https://doi.org/10.3109/02841869609083964
https://doi.org/10.3109/02841869609083964
Autor:
M. Espié, N. Bogdanova, J. Vinholes, Z. Shen, Z. Jiang, Y. Cheng, Diana Crivellari, Mikhail Lichinitser, M. Just, Ian E. Smith, Florence Dalenc, G.L. Vivanco, E. Chmielowska, R. Delva, E. Di Vincenzo, Z. Chen, Vladimir Semiglazov, Laura Biganzoli, C. Hamm
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 23(1)
Background: There are limited data on treatment outcomes in the growing population of elderly patients with locally recurrent/metastatic breast cancer (LR/mBC). To gain information on first-line bevacizumab combined with chemotherapy in the elderly,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c2cfd8480dcc92cfe1e475837ca96f4
https://pubmed.ncbi.nlm.nih.gov/21444356
https://pubmed.ncbi.nlm.nih.gov/21444356
Autor:
M. Kronfeld, J. Vinholes, M. Zampese, Gilberto Schwartsmann, E. Sander, A. L. Brunetto, Eduardo Sprinz, R. Preger, Luciane Kalakun
Publikováno v:
European Journal of Cancer and Clinical Oncology. 27:1637-1639
Antitumour activity of cytotoxic agents, evaluated in patients with AIDS-related Kaposi's sarcoma (KS), is about 30–80%. However, responses are mostly partial and short. Experience with etoposide is similar. Teniposide has a longer elimination half
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60596800ad22601a13839d9d46c19c3c
https://doi.org/10.1016/0277-5379(91)90434-f
https://doi.org/10.1016/0277-5379(91)90434-f